ABSTRACT. To assess the clinical usefulness of urinary growth hormone (UGH) measurements, a UGH determination technique, including dialysis, ultrafiltration, and measurement by polyclonal-coated tube RIA, was established. Sixty-three short children were studied: 56 idiopathic growth retarded (37 prepubertal and 19 pubertal) and seven prepubertal with classic GH (growth hormone) deficiency. Forty-two healthy children (32 prepubertal and 10 pubertal) served as controls.
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In recent years UGH determination has been proposed as an alternative way of estimating spontaneous GH production. However, the low concentration of GH in urine, far below the sensitivity of assays used for GH determination in serum, and the presence of interfering substances in normal urine make UGH determination difficult. Different strategies basically involving sample dialysis and concentration have been used to overcome these problems (1) (2) (3) (4) (5) (6) . Alternatively, ultrasensitive immunoassays, which at present are commercially unavailable (7) (8) (9) , have been developed. Results vary according to the different techniques used for quantitation and the differences in protocols for sample collection and result expression.
We use a simple method in which UGH can be measured by a commercially available RIA after dialysis and one-step concentration (5, 10) . To assess the most clinically useful expression of UGH data, UGH was measured as the total amount per collection period and as the concentration per g of Cr. Differences among several groups (normal, GH-deficient, and growth-retarded children, normal adults, and acromegalic patients), the effect of r-hGH treatment, and correlations with endogenous GH secretion and other parameters related to growth were studied.
PATIENTS AND METHODS

PATIENTS
Twenty-four-h Urine Studies. Control group. Forty-two healthy children [height > 10th percentile for age and sex according to Tanner's charts (1 I)] were classified into two subgroups: prepubertal (1 8 boys and 14 girls; age range 5.1 to 12.6 y; mean 8.9 y) and pubertal (Tanner stages 2-3: seven boys and three girls; age range 11.9 to 16.7 y; mean 13.5 y).
Idiopathic growth retardation. Fifty-six short but otherwise healthy children (height < the 3rd percentile for age and sex and normal GH response to provocative stimuli) were divided into two subgroups: prepubertal (28 boys and nine girls; age range 4.2 to 14.4 y, mean 10.7 y; mean SDS for height -2.47, range 73.7 to -2.0) and pubertal (Tanner stages 2-3: 13 boys and six girls; age range 10.8 to 16.7 y, mean age 14.0 y; mean SDS for height -2.5, range -4.8 to -2.1).
In addition, in 23 patients, 24-h urine samples were collected as day and night urine. Night urine consisted of that produced during the sleep period and the first morning voiding. UGH was determined in day and night urine samples as well as in a 24-h sample consisting of a proportional mixture of the corresponding day and night volumes.
GH-deficient group. Seven prepubertal children (five boys, two girls) who met clinical criteria for GH deficiency and failed to respond to two different GH stimulation tests were included in this group.
Acromegaly group. Eight adult patients with active acromegaly and increased plasma IGF-I concentrations, increased baseline plasma GH levels that were not suppressed below 5 pg/L after an oral glucose load, and/or a paradoxical GH rise in response to thyrotropin-releasing hormone were included in this group.
Adult control group. Eleven healthy, nonobese adults (seven women, four men) aged between 28 and 45 y made up this group.
Recombinant hGH-treated group. In 13 prepubertal children (two GH deficient and 11 growth retarded) treated with r-hGH (0.5 IU/kg/wk divided into daily evening doses), UGH excretion was determined before the start of treatment and at 6 and 12 mo of GH therapy.
Endogenous GH Secretion Studies. Forty children [28 boys, 12 girls; 31 prepubertal, nine pubertal; mean chronologic age 1 1.8 y (range: 6.3-16.0 y)] were studied. Five had normal growth, 31 had growth retardation, and four were diagnosed with GH deficiency; all underwent a 24-h integrated secretion study after their parents had given written informed consent. They were admitted the night before the study. The following morning, an indwelling nonthrombogenic catheter was placed in a forearm vein and blood collection tubes were replaced every 30 min during the next 24 h using a continuous withdrawal pump (Cormed Ambulatory Withdrawal System, model ML 6-5 H; Cormed Inc., Medina, NY). After serum separation, aliquots from the 30-min samples were combined to produce 24-h pools in which IC-GH was measured. Urine was collected during the same 24-h period.
METHODS
Collection, dialysis, and concentration of urine samples.
Twenty-four-h urine samples were collected and kept at 4°C throughout the collection period. Total volume was recorded and 50 pL of 100 g/L BSA were added to 50-mL aliquots of each sample to reach a BSA concentration of 1 g/L. The urine was centrifuged to remove debris, and urinary Cr concentration was determined by reaction with picric acid in an automatic analyzer (Technicon RA-1000; Technicon Instruments Corp., Tarrytown, NY). Urine aliquots were stored at -20°C until assayed.
After thawing, urine was dialyzed (dialysis sacks, 250-7U; Sigma Diagnostics, St. Louis, MO) against 0.1 M phosphate buffer, pH 7.4, at 4°C for 48 h. Dialyzed urine was concentrated by centrifugal ultrafiltration at 4"C, 2000 x g, using Centrifugal Ultrafree units UFC2 TGC 02 (Millipore Corp., Bedford, MA) equipped with a 10 000-D nominal molecular weight limit polysulfone membrane. These units permit 30-to 60-fold concentration of a starting volume of 18.5 mL in approximately 2 h. The volume of ultrafiltered samples was measured and a concentration factor calculated for each sample.
GH RIA. GH measurements in serum and concentrated urine samples were performed in duplicate by a polyclonal-coated tube RIA (SF-20 10 1 ; Spectria Farmos Diagnostica, Turku, Finland) using an anti-GH antiserum raised in rabbit (OH003) and calibrated against the WHO IRP 661217. Sensitivity of the RIA assay calculated at 2 SD from zero GH concentration was 0.23 pg/L. Sensitivity for urine samples after concentration (50-fold) was 4.6 ng/L (0.46 pgltube). Intra-and interassay coefficients of variation were 8.4 and 14.5% at 1.5 pg/L and 3.9 and 6.6 at 15 pg/L,I respectively. After dialysis and concentration, recovery of added GH (different amounts of GH were added to urine samples to obtain GH concentrations between 0.03 and 0.12 pg/L) was 86.9% (range 79. 8 Twenty-four-h UGH correlated significantly with day ( p < cluded prepubertal and pubertal control, growth-retarded, and 0.00 1) and night ( p < 0.001) UGH either expressed as ng/time GH-deficient children, UGH (ng/24 h) correlated significantly or as ng/g Cr. When UGH was expressed as the amount of GH with IC-GH, serum IGF-I concentration, chronologic age, and per period of time, no differences were found between 24-h and growth velocity. However, when UGH was expressed as ng/g Cr, the sum of day and night, and night UGH was lower than day correlations between UGH and serum IGF-I and chronologic UGH ( p < 0.04), although in an individual analysis eight of the age were lost and the statistical significance with growth velocity 22 patients had night UGH excretion higher than day UGH worsened. Our study shows that UGH expressed as ng/24 h excretion. When UGH was expressed as ng/g Cr, night excretion correlates better with biologic and auxologic parameters than was significantly lower than 24-h ( p < 0.003) and day excretion when expressed as ng/g Cr. SDS for height revealed no correla-( p < 0.03).
UGH in 24-h, day, and night urine samples.
tion with UGH in any case. Effect of r-hGH treatment on UGH excretion. UGH excretion In our study, the total amount of UGH during the day was (ng/24 h, mean + SD) before treatment (12.9 + 6.5) was signif-significantly higher than that during the night, but this was not icantly lower than at 6 mo (34.0 + 16.7, p < 0.003) and 12 mo constant in all children, as already reported by Girard et al. (8) .
(38.9 k 14.2, p < 0.002) of r-hGH treatment. Similar differences Moreover, when UGH was expressed per g of Cr, night UGH were found between GH excretion (ng/g Cr) before (22.3 + 1 1.9) was significantly lower than 24-h and day UGH. Although UGH and after 6 (48.5 + 21.5, p < 0.003) and 12 mo (47.8 + 10.9, p in day and night urine correlated closely with 24-h UGH per < 0.002) of treatment. No differences were found between UGH period of time or per g of Cr, as reported by Girard and Fischerexcretions at 6 and 12 mo. Wasels (17), we believe that UGH expressed as ng/24 h might Relationship of UGH to IC-GH, IGF-I, age, growth velocity, be the best index of GH secretion and might avoid differences and SDS for height. Table 3 shows the mean + SD and range of in interindividual day-to-night variations.
age, SDS for height, growth velocity, serum IGF-I concentrations UGH in prepubertal children treated with r-hGH significantly and IC-GH of the endogenous secretion study group. UGH increased when expressed either as ng/24 h or ng/g Cr, as also excretion expressed as ng/24 h correlated significantly with IC-reported by others (3, 6, 17, 2 1, 29) . UGH determination may GH ( p < 0.0001), baseline plasma IGF-I concentration ( p = permit assessment of the effect on endogenous GH secretion of 0.01), chronologic age ( p < 0.02), and growth velocity ( p < any treatment capable of modifying it: an increase has been 0.0001). UGH excretion expressed as ng/g Cr correlated signifi-demonstrated under testosterone or estrogen treatment (6, 17) , cantly with IC-GH ( p < 0.0001) and growth velocity ( p = 0.001) whereas no change could be observed during a clonidine treatbut not with IGF-I or chronologic age. No correlation was found ment trial (10). between UGH excretion and SDS for height.
In conclusion, UGH determination is a noninvasive, easily repeatable way of assessing GH secretion. Expression of UGH DISCUSSION per g of Cr avoids errors in urine collection and time control; however, because urinary Cr is not homogeneously excreted Different methods (1-l0,12) have been used to measure UGH, throughout the 24-h period and varies axording to age and body which has been shown to reflect endogenous GH secretion (5,6, mass, when UGH was corrected Per g of urinary Cr the increased 12-18) and to enable detection of plasma GH concentration GH secretion that occurs in puberty as well as the correlation variations in response to provocative stimuli (4, 12, 13, 17, 19, with IGF-I and age were lost. Differences among children be-20) in individuals with preserved renal function. However, there tween day and night UGH have also been observed. Conseis a lack of agreement in the literature as to which method is the quently, UGH expressed as the total m~o u n t Per 24 h would best for collecting and expressing UGH data, because results of appear to be a more advantageous approach to the expression of different collection periods (from minutes to 24 h) expressed UGH data for clinical Purposes. either as total UGH amounts Der veriod. Cr excretion. bodv * surface area, or weight have been reported. ' In our series, UGH excretion (ng/24 h) clearly differed in some groups (GH-deficient versus prepubertal controls or idiopathic short children; prepubertal versus pubertal; adult controls versus acromegalic patients), as already reported (3, 12, (14) (15) (16) (17) (18) (20) (21) (22) (23) . However, the increased GH secretion in puberty (24, 25) reflected in UGH excretion (12, 15, 17, 22) disappeared when UGH was expressed as ng/g Cr. Previous reports have documented that Cr excretion varies as a function of body muscle mass (26) ; thus, to express UGH per g of Cr may result in falsely low UGH values in puberty, as has been suggested by others (18, 20) .
Twenty-four-h endogenous GH secretion has been reported to correlate with other parameters related to growth, such as IGF-I (25), growth velocity (27) , chronologic age (24) , and SDS for height (28) . Some authors have demonstrated correlations between UGH and IGF-I (14, 16) and UGH and growth velocity (15). In our endogenous GH secretion study group, which in- 
